Skip to content
Biodatica
Start free

Biomea Fusion Inc.

Goodyear, Arizona

Oncologysmall moleculePhase IListed · BMEA

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

NIH U2F · $0.1M · RRT Maintenance Pennsylvania Department of Agriculture (PDA)

Jun 2025Grant renewalJun 24, 2025Source filing (opens the source filing in a new tab)

Momentum

42no change

Momentum 42 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    R01 · $567k · non-dilutive

    Mar 1, 2025

    BRIGHAM AND WOMEN'S HOSPITAL · PI MORRIS, SAMANTHA ANNETTE · NIDDK · award ends Feb 29, 2028 · Decoding the Molecular Mechanisms Underlying Reprogramming to Functional Hepatic and Intestinal Cell Types

    NIH RePORTER · NIH RePORTER 11261401 (opens the source filing in a new tab)

  2. Grant

    R35 · $449k · non-dilutive

    Mar 5, 2024

    BRIGHAM AND WOMEN'S HOSPITAL · PI MORRIS, SAMANTHA ANNETTE · NIGMS · award ends Jan 31, 2029 · Decoding the Molecular Mechanisms Governing Regulation and Reprogramming of Cellular Identity

    NIH RePORTER · NIH RePORTER 11222535 (opens the source filing in a new tab)

  3. Grant

    U2F · $131k · non-dilutive

    Sep 1, 2023

    PENNSYLVANIA DEPARTMENT OF AGRICULTURE · PI KLINE, KELLY · FDA · award ends Mar 31, 2027 · RRT Maintenance Pennsylvania Department of Agriculture (PDA)

    NIH RePORTER · NIH RePORTER 11145091 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Jan 12, 2023

    Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC, PDAC, CRC, Relapsed Cancer, Refractory Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Stage III Colorectal Cancer, Stage IV Colorectal Cancer, Stage III NSCLC, Stage IV NSCLC, KRAS Mutation-Related Tumors · TERMINATED · sponsor: Biomea Fusion Inc. · Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

    ClinicalTrials.gov · NCT05631574 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources